Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication

 
• By Alaric DeArment
  
BMS will continue a Phase III pivotal trial of Opdivo in first-line bladder cancer after a primary endpoint setback • Source: Shutterstock

More from Anticancer

More from Therapy Areas